Preconditioning Chemotherapy Combination With Cytokine Induced Killer Cell (CIK) Immunotherapy
Status:
Unknown status
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
This clinical Trial is proposed to explore whether preconditioning chemotherapy of
Paclitaxel+cisplatin(TP)regimen combined with autologous adoptive CIK cell immunotherapy
could benefit NSCLC patients with a better clinical outcome.